Novo Nordisk A/S (NVO): Price and Financial Metrics


Novo Nordisk A/S (NVO): $74.15

-0.08 (-0.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NVO Stock Summary

  • With a market capitalization of $174,440,500,000, Novo Nordisk A S has a greater market value than 98.88% of US stocks.
  • Novo Nordisk A S's stock had its IPO on January 1, 1986, making it an older stock than 92.8% of US equities in our set.
  • The volatility of Novo Nordisk A S's share price is greater than that of only 0.87% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Novo Nordisk A S are SAP, NVS, ABBV, AZN, and MDT.
  • NVO's SEC filings can be seen here. And to visit Novo Nordisk A S's official web site, go to www.novonordisk.com.

NVO Stock Price Chart Interactive Chart >

Price chart for NVO

NVO Price/Volume Stats

Current price $74.15 52-week high $75.86
Prev. close $74.23 52-week low $61.53
Day low $73.86 Volume 655,400
Day high $74.51 Avg. volume 997,428
50-day MA $71.08 Dividend yield 1.79%
200-day MA $69.16 Market Cap 174.61B

Novo Nordisk A/S (NVO) Company Bio


Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The company was founded in 1925 and is based in Bagsvaerd, Denmark.

NVO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$74.15$176.86 138%

We started the process of determining a valid price forecast for Novo Nordisk A S with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Novo Nordisk A S ranked in the 73th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 139.5%. In terms of the factors that were most noteworthy in this DCF analysis for NVO, they are:

  • As a business, NVO is generating more cash flow than 99.11% of positive cash flow stocks in the Healthcare.
  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately only 7.07% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • NVO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 53.36% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%134%
1%136%
2%138%
3%141%
4%143%
5%145%

Want more companies with a valuation profile/forecast similar to that of Novo Nordisk A S? See RDNT, AMN, KMDA, SIGA, and CVS.


NVO Latest News Stream


Event/Time News Detail
Loading, please wait...

NVO Latest Social Stream


Loading social stream, please wait...

View Full NVO Social Stream

Latest NVO News From Around the Web

Below are the latest news stories about Novo Nordisk A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.

Novo Nordisk to begin late-stage trial for oral semaglutide in obesity

Novo Nordisk ([[NVO]] +0.8%) announced its plans to initiate a global Phase 3 trial in H2 2021 for oral semaglutide 50 mg in obesity.The pivotal Phase 3a program is set to enroll ~1K people with obesity or overweight with comorbidities.The study will run for 68 weeks and evaluate the efficacy and...

Seeking Alpha | April 21, 2021

No­vo Nordisk To Start Phase 3 Obe­si­ty Tri­al With Oral Semaglu­tide

Novo Nordisk A/S (NYSE: NVO ) is entering the Phase 3a study in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a trial with once-weekly subcutaneously administered semaglutide 2.4 mg. The company will launch the trial in the second half of … Full story available on Benzinga.com

Benzinga | April 21, 2021

Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide

Bagsværd, Denmark, 21 April 2021 – Novo Nordisk today announced the decision to enter phase 3a development in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a clinical programme with once-weekly subcutaneous (sc) semaglutide 2.4 mg. Novo Nordisk intends to initiate a pivotal phase 3a programme with approximately 1,000 people with obesity or overweight with comorbidities. The global 68-week trial is planned for initiation in the second half of 2021 and will investigate the efficacy and safety of oral semaglutide compared to placebo. “There is a significant unmet medical need within obesity treatment today. With oral semaglutide we aim to introduce a convenient and effective treatment option for people with obesity and healthcare providers enab...

Yahoo | April 21, 2021

The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Honeywell International, Novo Nordisk and Starbucks

The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Honeywell International, Novo Nordisk and Starbucks

Yahoo | April 20, 2021

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 19 April 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 3 February 2021. Under the programme initiated 3 February 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 3 February 2021 to 3 May 2021. Since the announcement as of 12 April 2021, the following transactions have been made: Number ofB sharesAveragepurchase priceTransactionvalue, DKKA...

Yahoo | April 19, 2021

Read More 'NVO' Stories Here

NVO Price Returns

1-mo 11.67%
3-mo 2.82%
6-mo 5.86%
1-year 17.69%
3-year 65.44%
5-year 42.78%
YTD 7.21%
2020 22.56%
2019 27.79%
2018 -12.54%
2017 52.92%
2016 -37.03%

NVO Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full NVO Dividend History

Continue Researching NVO

Want to see what other sources are saying about Novo Nordisk A S's financials and stock price? Try the links below:

Novo Nordisk A S (NVO) Stock Price | Nasdaq
Novo Nordisk A S (NVO) Stock Quote, History and News - Yahoo Finance
Novo Nordisk A S (NVO) Stock Price and Basic Information | MarketWatch

Page generated in 1.0991 seconds.